Washington Trust Advisors, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Washington Trust Advisors, Inc.
- $1.09 Billion
- Q1 2025
A detailed history of Washington Trust Advisors, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 175 shares of ALNY stock, worth $52,930. This represents 0.0% of its overall portfolio holdings.
Number of Shares
175
Previous 114
53.51%
Holding current value
$52,930
Previous $26,000
80.77%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ALNY
# of Institutions
720Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$5.07 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$3.95 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.89 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.16 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.34 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $37.2B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...